P52 | Hyperobese women: what is the best treatment to prevent progression to severe forms of COVID-19 infection?
P. Crispino1, S. De Taddeo1, G. Guarisco2, G. Aprea1, A. Palladino1, C. Galasso1, M. Testa1, L. Ottaviani1, F. Cardoni1, M. Lichtner3 | 1UOC Medicina Interna, Ospedale Santa Maria Goretti, Latina, 2UOC Diabetologia, Ospedale Santa Maria Goretti, Latina, 3Dipartimento di Area Medica, Ospedale Santa Maria Goretti, Latina, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Obesity is considered one of the main risk factors for the development of a severe form of COVID-19, involving several mechanisms. The present study aimed to evaluate the impact of antiviral agents (AA) and monoclonal antibody therapy (MoAb) in this population.
Methods: We examined 96 female patients (33,9±4,04 years old, BMI: 37,8±6,6 kg), associated with other age-related comorbidities, treated for COVID-19 infection, evaluating the times to negativization (TN) and the long-term sequelae. Values are given as medians and non-parametric Mann–Whitney tests were applied to compare the differences in values. All statistical analyses were considered significant with p-values<0.05.
Results: Comparing patients treated with MoAb s vs. AA, the median TN is 16 vs. 8 days (z-score is -3.09; p:0.002). Comparing vaccinated vs. unvaccinated patients, the median TN is 9 vs. 18.5 days (z-score is -3.18; p: 0.001. In unvaccinated patients, the median TN was 19 days in the MoAb group vs. 15 days in the AA group (z-score is 0.2; p:0.83). MoAb in vaccinated vs. unvaccinated patients, showed a median TN of 14 vs. 19 days (z-score is -0.64; p:0.51. Comparing AA in vaccinated vs. unvaccinated the median TN is 7.5 vs. 15 days (z-score -3; p:0.0027).
Conclusions: In hyperobese female patients who have risk factors for progression to severe disease, vaccination is recommended. Compared to MoAbs, AA obtains a significantly shorter eradication time of COVID-19 and therefore fewer short and long-term sequelae.
Altmetrics
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.